| Skin Cancer |
1 |
0.8 |
| Psoriasis |
0 |
0.68 |
| Squamous Cell Carcinoma |
0 |
0.56 |
| Cancer |
0 |
0.53 |
| Porokeratosis |
0 |
0.53 |
| Human Papillomavirus |
0 |
0.49 |
| Biopsy |
0 |
0.35 |
| Tumor |
0 |
0.27 |
| Anti-Tumor Necrosis Factor (Anti-TNF) |
0 |
0.25 |
| Mohs Surgery |
0 |
0.25 |
| Tumor Necrosis Factor-Alpha |
0 |
0.25 |
| Genomic Medicine |
0 |
0.21 |
| Epidermal Growth Factor Receptor |
0 |
0.19 |
| Adverse Effects |
0 |
0.18 |
| Brachial |
0 |
0.18 |
| Immunocompromise |
0 |
0.18 |
| Nodule |
0 |
0.18 |
| Receptors |
0 |
0.18 |
| Surgery |
0 |
0.18 |
| Spondylitis, Spondylosis, Kyphosis |
0 |
0.17 |
| Patient Safety |
0 |
0.16 |
| Rheumatoid Arthritis |
0 |
0.11 |
| Ankylosing Spondylitis |
0 |
0.09 |
| Arthritis |
0 |
0.09 |
| CT Scan |
0 |
0.09 |
| Lymphadenopathy |
0 |
0.09 |
| Outpatient Clinic |
0 |
0.09 |
| Papillomavirus |
0 |
0.09 |
| Positron Emission Tomography (PET) |
0 |
0.09 |
| Retinoids |
0 |
0.09 |
| Wart |
0 |
0.09 |
| Health Care Reform |
0 |
0.08 |